Better Buy: AST SpaceMobile or Rocket Lab?

Rocket Lab is favored as the better buy: market caps are ~$37B for Rocket Lab vs ~$33B for AST SpaceMobile and the stocks trade at roughly 31x and 42x their 2027 revenue estimates, respectively. Rocket Lab has secured a $190M contract for 20 HASTE suborbital launches and a Space Development Agency satellite contract potentially worth up to $816M, providing diversified government-driven revenue paths. AST SpaceMobile is expanding a space-based cellular broadband constellation and has partnerships with 50+ mobile operators to address coverage for nearly 6B people, but it must continue successful launches to scale. Key risks include Rocket Lab's Neutron reusable-rocket development and head-to-head competition with SpaceX, and AST's execution risk building its satellite network.

Analysis

Rocket Lab's pathway to durable margins is more structurally diversified: government programs create predictable programmatic revenue with multi-year procurement tails, while launch and spacecraft services enable cadence-driven margin improvement as fixed costs amortize. The more concentrated commercial constellation model faces a two-layer execution cliff — hardware supply-chain scale and commercial partner monetization — meaning near-term unit economics can swing wildly if either layer lags.

A critical second-order effect is launch cadence mismatch: if satellite manufacturers outpace reliable lift availability, inventory and working-capital stress forces either expensive third-party launches or equity dilution to bridge timing gaps. Conversely, a persistent gap in medium-lift reusable capacity among incumbents preserves a pricing umbrella for lower-frequency launch providers; the timing of any reusable-demo success therefore compresses the window in which non-incumbents can capture outsized margins.

Regulatory and telco-commercial gating will dominate short-to-medium-term outcomes. Anchoring deals that convert into multi-year ARPU and roaming agreements are binary events that can re-rate a constellation name within 6–18 months, while successful demonstration flights and tranche awards will materially de-risk a launch/defense name over a 12–24 month horizon. The largest downside tail is not technology per se but partner churn, spectrum/regulatory denial, or a high-profile launch failure that resets both fundraising and go-to-market timelines.

Key Decisions for Investors

• Go long RKLB (common equity) with a 12–24 month horizon: accumulate on >15% intraday pullbacks or after tranche- award headlines, target asymmetric return of 1.5x–3x with stop at 25% drawdown; thesis: government program visibility + amortizing fixed costs.
• Pair trade — long RKLB / short ASTS (equal notional) for 6–12 months: expresses view that programmatic government revenue is less binary than MNO-dependent constellation monetization. Hedge the short with bought calls on ASTS to limit parity blow-ups (cost = premium).
• Buy ASTS downside protection: purchase 9–12 month puts sized to ~25% of a broader portfolio position rather than outright shorting, targeting tail-risk payoff if partner churn or regulatory setbacks materialize; cost-defined downside with limited capital at risk.
• Play the upstream compute/sensor exposure via NVDA (selective size) for a 12–36 month hold: benefit from secular on-orbit processing and inference demand while avoiding pure-play constellation execution risk. Position size modest (underweight core) — reward = secular multiple expansion; risk = cyclic semiconductor drawdown.